New Horizons in Cardio Kidney Disease, is a new one-day virtual educational event that took place live on 30 June 2026, designed to address current challenges in cardio-kidney care through practical, cross-disciplinary education, with a focus on biomarker-guided risk assessment, optimisation of blood pressure and cardio-kidney therapies, and emerging multimodal strategies.
Led by course directors Dr Muthiah Vaduganathan (Brigham and Women's Hospital, Boston, US), Dr Neha Pagidipati (Duke Clinical Research Institute, Durham, US), and Prof Smeeta Sinha (Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, UK), the programme features expert-led presentations, case-based discussions, and multidisciplinary panel sessions. This interactive, collaborative format reflects real-world care pathways and supports the wider implementation of evidence-based strategies in clinical practice.
Watch the full on-demand series* to stay at the forefront of cardio-kidney disease management and enhance your practice with the latest clinical insights.
*Please note, the live version of New Horizons in Cardio Kidney Disease was accredited. This on-demand version is not.
The symposium 'Clinical Utility of eGFR Slope Across Cardio-Kidney Care and Trial Design' is also available to watch here (This session is not intended for UK based HCPs).
Key Learning Objectives
- Increase confidence interpreting albuminuria and integrating biomarkers into risk models
- Improve confidence interpreting BP phenotypes and organ-injury signals to inform escalation decisions
- Improve understanding of therapy sequencing and combination approaches
- Greater adoption of multidisciplinary care pathways
- Enhance readiness for emerging multimodal strategies
Target Audience
- Cardiologists
- Nephrologists
- Primary Care Physicians
- Diabetes Specialists
- Endocrinologists
More from this programme
Part 1
New Horizons in Cardio Kidney Disease: Welcome and Introduction
Neha Pagidipati (Durham, US) and Smeeta Sinha (Salford, UK) introduce the programme and share the key learning objectives.
| 1 session | |
| Welcome and Introduction | Watch now |
Part 2
Session 1: Defining Persistent Risk in Cardio Kidney Disease
Neha Pagidipati (Durham, US) chairs the first session, where faculty focus on defining persistent risk in cardio-kidney disease and exploring the mechanisms that have the greatest relevance for clinical practice. She is joined by Katherine Tuttle (Seattle, US), Erika Jones (Cape Town, SA) and Shelley Zieroth (Winnipeg, CA) for presentations and panel discussion.
Part 3
Session 2: Biomarkers That Guide Decisions
Smeeta Sinha (Salford, UK) chairs this session which demonstrates how biomarkers can identify high-risk patients earlier and enable more informed treatment decisions. She is joined by Navdeep Tangri (Winnipeg, CA), Neha Pagidipati (Durham, US) and Alta Schutte (Sydney, AU) for presentations and panel discussion.
Part 4
Session 3: Optimising Care, From Guidelines to Practice
Muthiah Vaduganathan (Boston, US) chairs this session, which translates risk identification into risk reduction by exploring therapeutic classes and strategies within the context of guideline-directed care, residual risk, and multimodal protection. He is joined by Biykem Bozkurt (Houston, US), Anjay Rastogi (Los Angeles, US) and Hiddo J L Heerspink (Groningen, NL) for presentations and panel discussion.
Part 5
Session 4: Coordinating Multidisciplinary Cardio Kidney Risk Management
Neha Pagidipati (Durham, US) chairs this session and is joined by Anjay Rastogi (Los Angeles, US), Muthiah Vaduganathan (Boston, US) and Smeeta Sinha (Salford, UK). The session explores how multidisciplinary care can improve outcomes.
Part 6
Session 5: Case-Based Decisions Translation
Muthiah Vaduganathan (Boston, US) chairs the final session, a case-based panel discussion that brings together key themes from the previous sessions. A global multidisciplinary panel featuring Jeff Borenstein (Los Angeles, US), Biykem Bozkurt (Houston, US), Erika Jones (Cape Town, SA), Nicholas Jones (Oxford, UK) and Katherine Tuttle (Seattle, US) share their perspectives.
The panel review a case of a 72-year-old male patient. Beyond the case discussion, the panel explore applying biomarker findings to real-world decision-making, navigating therapy sequencing in patients with residual cardio-kidney risk, and identifying multidisciplinary decision points across cardiology, nephrology, and primary care.
Part 7
New Horizons in Cardio Kidney Disease: Close and Key Takeaways
Muthiah Vaduganathan (Boston, US) brings New Horizons in Cardio Kidney Disease 2026 to a close, sharing key insights and takeaways from the day.
| 1 session | |
| Close and Key Takeaways | Watch now |
Faculty Biographies
Neha Pagidipati
Assistant Professor of Medicine
Neha J Pagidipati is an Assistant Professor of Medicine and cardiovascular disease prevention specialist. Since 2011, she has conducted research on cardiometabolic disease prevention, lifestyle modification and weight management. She is currently an NIH K12 scholar in Implementation and Dissemination Science.
Dr Pagidipati is building the Duke Cardiometabolic Disease Prevention Program, which focuses on behavior change and risk factor management in patients with high risk of cardiovascular and metabolic diseases such as diabetes and obesity.
Dr Pagidipati’s research grants include the COORDINATE-Diabetes Trial, to improve the quality of care for patients with diabetes and cardiovascular disease across the US, and QuBBD: Deep Poisson Methods for Biomedical Time-to-Event and Longitudinal Data.
In addition, she is leading a large study within the Duke Health System to study heterogeneity within cardiovascular disease risk and…
Katherine Tuttle
Executive Director of Research
Dr Katherine R Tuttle, is Professor of Medicine in the Nephrology Division and Kidney Research Institute at the University of Washington, US. Executive Director for Research at Providence Inland Northwest Health, and a Co-Principal Investigator for the ITHS. Her major research interests are in the areas of clinical and translational science and precision medicine for diabetic kidney disease, chronic kidney disease, diabetes, and hypertension. Dr Tuttle has led a major patient registry as well as clinical trials in these fields that have delivered breakthrough therapies to prevent kidney failure and cardiovascular events.
Erika SW Jones
Nephrology and Hypertension Specialist
Dr Erika Jones is Associate Professor in the Division of Nephrology and Hypertension at the University of Cape Town and Groote Schuur Hospital in Cape Town, SA.
Dr Jones interests are particularly in hypertension, having done her PhD in this area. One of the aspects of hypertension that she is studying currently and which is of major concern to nephrologists in Cape Town, is the rising incidence of young hypertensives with end stage renal disease in relation to methamphetamine usage.
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.